Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies
Executive Summary
UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.